This message contains images. If you don't see images, click here to view.
Advertise in this news brief.
Advertisement
|
|
Advertisement
Advertisement
.jpg)
Advertisement
On-demand SLAS scientific presentations from the convenience of your home or office via your preferred device.
|
|
|
Advertisement
SLAS2018 Short Course Program Preview
SLAS Share
   
Four new classes are among the SLAS2018 Short Courses to be held Saturday and Sunday, Feb. 3-4, San Diego, CA:
- 3D Printing for Scientific Applications
- Microcontrollers, the Internet of Things and our Laboratories
- Phenotypic Screening: Why, When and How
- Set-Up and Validation of 3D Primary, Stem Cell and Immortalized Cultures for Downstream Microplate Reader and Imaging Applications
Final titles, course descriptions and instructor details will be available in August.
More
Advertisement
Call for Papers: High-Throughput Flow Cytometry in Drug Discovery
SLAS Share
SLAS Discovery Guest Editors Mei Ding of AstraZeneca and Bruce S. Edwards of the University of New Mexico invite special issue manuscript proposals (abstracts) on high-throughput flow cytometry (HTFC) applications for drug discovery or target discovery; HTFC for antibody generation screening, biomarker discovery, biochemical applications; HTFC using multiplexing approaches; HTFC as an alternative for other assay platforms; insights and opinions on HTFC assay design and development; novel assays using HTFC; reagent developments for HTFC applications; developments in HTFC instruments and automation; and advances in HTFC data analysis software.
Proposal due date is Oct. 1.
More
SLAS Discovery Special Issue on 3D Cell Culture, Drug Screening and Optimization
SLAS Share
With free online access to select articles sponsored by Corning Life Sciences, the June 2017 SLAS Discovery Special Issue on 3D Cell Culture, Drug Screening and Optimization is gaining traction with emerging data that provide new insights into fundamental cell biology and better screening systems for novel agents entering clinical evaluation.
Guest Editors Richard M. Eglen of Corning Life Sciences and Jean-Louis Klein of GlaxoSmithKline invite you to search the issue today. Also, read the SLAS Electronic Laboratory Neighborhood e-zine article about the topic.
More
Advertisement
 |
Keep your CRISPR/Cas9 gene editing workflow moving smoothly with fast and reliable detection of positive clones. The AccuCleave™ T7CE Kit uses an optimized heteroduplex cleavage assay to quickly identify and characterize CRISPR induced modifications with fast and reliable detection on the Fragment Analyzer™ Automated CE System from Advanced Analytical.
|
Assay Development and Screening at SLAS2018
SLAS Share
Assay Development and Screening is one of ten SLAS2018 educational tracks accepting podium abstract submissions until Aug. 7. Track Chairs Edward Ainscow of Carrick Therapeutics and Ralph Garripa of Memorial Sloan Kettering Cancer Center say the continued development of novel and more physiologically relevant assay technologies combined with evolving strategies for compound, RNAi and CRISPR library screening seek to broaden both the scope of target classes that can be addressed and to improve high-throughput screening (HTS) success rates.
This track focuses on recent innovations across the field, including the application of new instrumentation, hardware and novel assay technologies to compound and genomic screening. Emphasis is on case histories where the technology has been developed and implemented in an HTS campaign and the triage process to confirm hits is described. See track session descriptions and the benefits of presenting on the SLAS2018 website.
More
Altmetrics Now Available to SLAS Journal Authors
SLAS Share
Because people now routinely use the web to communicate, more research is being shared, discussed, rated, recommended, reviewed and read online. Use and discussion of research that was previously hidden (because it was conducted offline or in print) is now discoverable and reported via Altmetrics.
Data-sourced from online discussions, Altmetrics complement citations in understanding the potential impact of published research.
To benefit SLAS journal authors, Altmetrics are now built into SLAS Discovery and SLAS Technology online functionality.
More
Advertisement
2017 SLAS Europe Nordic Chemical Biology Meeting a Success
SLAS Share
Some 130 chemical biology experts gathered June 6-7 at the University of Copenhagen to discuss and develop ideas regarding the quality/analysis of libraries prior to screening, open innovation initiatives, chemoproteomics, cancer immunotherapy and antimicrobial resistance and infectious disease.
Conference Chair Mads H. Clausen of the Technical University of Denmark and his committee recognize and thank presenters from The Arctic University of Norway, Harvard University, Lund University, Lygature, Neuroscience Drug Discovery, Novartis Institutes for Biomedical Research and Umeâ University among others. The meeting also included 40 scientific posters and six exhibitors.
More
New Frontier in Cancer Care: Turning Blood Into Living Drugs
Bioscience Technology Share
Ken Shefveland's body was swollen with cancer, treatment after treatment failing until doctors gambled on a radical approach: They removed some of his immune cells, engineered them into cancer assassins and unleashed them into his bloodstream.
Immune therapy is the hottest trend in cancer care and this is its next frontier — creating "living drugs" that grow inside the body into an army that seeks and destroys tumors.
More
Advertisement
Novel Sequencing Approach Seeks to Detect Cancer's Genomic Alterations
Lab Manager Share
Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect cancer in its earliest stages, according to research presented by a Memorial Sloan Kettering Cancer Center (MSK) investigator at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
More
Lab on a Chip Could Monitor Health, Germs and Pollutants
Science Daily Share
Imagine wearing a device that continuously analyzes your sweat or blood for different types of biomarkers, such as proteins that show you may have breast cancer or lung cancer.
Rutgers engineers have invented biosensor technology — known as a lab on a chip — that could be used in hand-held or wearable devices to monitor your health and exposure to dangerous bacteria, viruses and pollutants.
More
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach
Journal of the American Chemical Society Share
A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT.
More
Chemists Bring Mixed Folded Proteins to Life
Phys.org Share
Scientists from ITMO University in Saint Petersburg and Hebrew University in Jerusalem have found a way to recover a protein structure after its chemical denaturation. The method is based on electrostatic interaction between folded, or denatured, proteins and alumina, which unwrap them. The authors highlight the versatility of the method, which works for both specific molecules and multiprotein systems — no previous technique has been able to recover mixtures of enzymes before.
More
Gene Mutations Foretell Immunotherapy Response
The Scientist Share
An immune checkpoint blocker successfully treated a variety of tumors in patients with gene mutations in a DNA repair pathway, according to a study published in Science. Johns Hopkins University researchers and their colleagues demonstrated that the drug pembrolizumab eliminated, shrank or stopped the growth of tumors in 66 out of 86 patients with 12 different types of cancer.
More
NIH Abandons Controversial Plan to Cap Grants to Big Labs, Creates New Fund for Younger Scientists
Science Magazine Share
The National Institutes of Health (NIH) is dropping a controversial, one-month-old plan to cap the amount of support an individual scientist can receive in order to spread funds to more investigators. Instead, the agency will eventually devote $1 billion a year — about 3% of its $34 billion budget — specifically to funding proposals from early- and midcareer investigators.
More
Online Tool Connects Drug Industry to UK Academia
Chemical & Engineering News Share
The Association of the British Pharmaceutical Industry (ABPI) has launched a public, online database that allows researchers from U.K. universities and other organizations to identify opportunities for collaborating with major drug companies.
Called the Library of Initiatives for Novel Collaborations (LINC), the database includes listings of funding offers, access to equipment and compounds, and postings of preclinical and clinical research opportunities. Researchers can apply online.
More
Scientific Manager/Group Leader, Biologics Sample Management – Early Research and Development
Genentech
US – CA – South San Francisco
Associate Director for Clinical Chemistry
Geisinger Health System
US – PA – Danville
BioProduct Development Field Applications
Molecular Devices LLC
US – MA – Boston
Search Jobs at SLAS Career Connections
|
|
|
|
|
SLAS Point-to-Point
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit
Dennis Hall, Executive Editor, 469.420.2656
Contribute news
This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!
SLAS Terms of Use Policy
MultiView Privacy Policy
|
|
Recent issues
June 7, 2017
May 31, 2017
May 24, 2017
May 17, 2017
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
